Research misconduct found by FDA inspections of clinical trials is rarely reported in journal studiesBMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h747 (Published 10 February 2015) Cite this as: BMJ 2015;350:h747
- Susan Mayor
Apparent research misconduct identified during inspections of clinical trial sites by the US Food and Drug Administration (FDA) is rarely mentioned in subsequently published journal articles about the research, says a study that has highlighted a gap in the transparency of clinical trial reporting.
The review1 identified 57 published clinical trials for which an FDA inspection of one of the trial sites had found significant evidence of research misconduct, including falsification or the submission of false information, problems with adverse event reporting, or …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial